
Michigan Value Investor
1.5K posts

Michigan Value Investor
@Michigan_Value
Yup, it's really me, the one and only MVI
Do you really have to ask? Katılım Haziran 2024
75 Takip Edilen1.7K Takipçiler
Sabitlenmiş Tweet

$HROW It's always amazing to me how price moves dictate sentiment when the businesses themselves have done nothing materially different than expected. Consider ETON and HROW recently, both the subjects of my recent SA public articles. In each case I bought lower originally, $5.70 for HROW and $3.50 for ETON, but never mind that, let's just think about YTD 2026.
Nothing has changed about the value of either stock YTD. Everything long term is exactly what it's always been. That's something like $100 for ETON and something like $500 for HROW by the end of the decade, call it 2030. Anyone can easily see this for themselves by looking even the most basic long term metrics over time - revenue growth, EBITDA margin growth - and then asking if the elements are in place for continued growth, as they clearly are. The details are uncertain, as is the timing. But the basic range of value centering around these targets, there has been practically no news at all.
And yet... ETON's price from the lows YTD has doubled and HROW's price from the highs this year has been cut almost in half. Zero change in value, no news that matters to value has been learned, long term targets not changed. Short term prices have moved the relative price of these two stocks by a factor of 4.
In each case, the stocks are simple to understand and easy to model over longer periods. HROW in particular is harder to model quarter by quarter because of the huge seasonality and the issues surrounding regulation and insurance, neither of which apply to ETON. So on a quarterly basis, ETON is easy. But both are very simple over a period of years.
If you are a value investor, something will click about what I just said. Buffett always said value investing is simple, but it isn't easy. And that it doesn't take a lot of IQ - anything over 120 is a waste is what he said, not sure I agree - but the real trick is the right mindset. Someone losing their mind over this short term price movement and letting fanciful stories impact their decisions when the long term trends are as plain as day, that person may have the required 120+ IQ, but clearly lacks the right mindset.
Buffett always said, too, that you can't teach that mindset. It either makes sense to you or it doesn't. I include this commentary here for those who have that mindset, but who are second guessing themselves right now. If that's you, ignore the fearful short termers who let the market tell them what to think, think for yourself instead, and act according to your views. For the rest, I wish you well, good luck!
English

@Michigan_Value Potential is clearly there, but I will believe it when I see it. Growth and execution has been good but their guidance has always been optimistic. Just like yours AFAIK haha :)
English

$HROW long term trends are obvious, but an uptick in this trend is coming. Obvious that $250M in Q4 2027 is plausible. The reason is that the slow growing parts of the business have become a smaller part of the total compared to the fast growing parts. Look for Vevye $65M, Iheezo $50M, Triesence $15M in Q4 2026. That's $130M just from those 3 drugs in just one quarter. In 2023 whole company full year revenue was $130M.
Then we need to add Immy, maybe $15M, and other branded (OB), and Byooviz. OB is going to shock people maybe in Q4 2026, but definitely in 2027. Massive opportunities being unlocked here, so much so that it now has a VP in charge and a sales force. $15M in 2025 for the year, $6M in Q1 2026. Tailwinds are in part from this salesforce, and in part from Beagle - that's where Immy drugs are being branded into OB, so really just moving revenue from one bucket to another.
But then they will launch Byqlovi, and Iopidine now has a J-code, and now we know Verkazia is a huge opportunity. They will launch Verkazia to treat childhood seasonal allergies. 7M US kids with a diagnosis. ASP unknown, but WAC is $1900, plenty of room. No real competition, just steroids or OTC crappy drops. Verkazia is likely another $100M+ drug, not in 2026, but it will begin.
These are huge tailwinds. OB will shock people, maybe $15M in Q4 2026 but heading up fast. Byooviz launch will add some, not sure on that, and then Opuviz in 2027. But we are already at a big number in Q4 2026. That adds up fast, already $150M+, and when they show that, no one will doubt $250M in Q4 2027.
Full year guidance raise in Q3 2026 will hint at the strong Q4 coming. This is when the market will start to do the math on Q4 2027. But many will know before then...
Historical revenue = obvious

English

@semodough you think the market is focused on Melt? That would surprise me. It would mean being forward looking by a few years... agree that the market questions mgmt credibility though. I love them, but the market care a lot about guidance
English


@Michigan_Value $HROW over promises and under delivers. That is a 68 IQ.
English

$HROW It's always amazing to me how price moves dictate sentiment when the businesses themselves have done nothing materially different than expected. Consider ETON and HROW recently, both the subjects of my recent SA public articles. In each case I bought lower originally, $5.70 for HROW and $3.50 for ETON, but never mind that, let's just think about YTD 2026.
Nothing has changed about the value of either stock YTD. Everything long term is exactly what it's always been. That's something like $100 for ETON and something like $500 for HROW by the end of the decade, call it 2030. Anyone can easily see this for themselves by looking even the most basic long term metrics over time - revenue growth, EBITDA margin growth - and then asking if the elements are in place for continued growth, as they clearly are. The details are uncertain, as is the timing. But the basic range of value centering around these targets, there has been practically no news at all.
And yet... ETON's price from the lows YTD has doubled and HROW's price from the highs this year has been cut almost in half. Zero change in value, no news that matters to value has been learned, long term targets not changed. Short term prices have moved the relative price of these two stocks by a factor of 4.
In each case, the stocks are simple to understand and easy to model over longer periods. HROW in particular is harder to model quarter by quarter because of the huge seasonality and the issues surrounding regulation and insurance, neither of which apply to ETON. So on a quarterly basis, ETON is easy. But both are very simple over a period of years.
If you are a value investor, something will click about what I just said. Buffett always said value investing is simple, but it isn't easy. And that it doesn't take a lot of IQ - anything over 120 is a waste is what he said, not sure I agree - but the real trick is the right mindset. Someone losing their mind over this short term price movement and letting fanciful stories impact their decisions when the long term trends are as plain as day, that person may have the required 120+ IQ, but clearly lacks the right mindset.
Buffett always said, too, that you can't teach that mindset. It either makes sense to you or it doesn't. I include this commentary here for those who have that mindset, but who are second guessing themselves right now. If that's you, ignore the fearful short termers who let the market tell them what to think, think for yourself instead, and act according to your views. For the rest, I wish you well, good luck!
English

@Michigan_Value Management is missing guidance every fucking quarter. If you don’t have a clue what your revenues will be, don’t issue guidance man, and obviously it’s a shitty business, since they don’t have pricing power.
English

@Michigan_Value Funny how this management team built a $1B company from zero yet people allow themselves to doubt how capable they are and say that they have lost all credibility.
English

@RevShark They are concerned about building a business. Mark is an entrepreneur, and super smart. What he's doing is incredibly hard, and the track record is just epic. But he does not get people. Neither did Buffett. He studied and learned how. Mark is still learning.
English

@Michigan_Value Momentum was the wrong word "positive price action' is what they should be concerned about. I'm not sure how smart these guys are if they can't understand that they are hurting their shareholder base.
English

@RevShark A momentum play is not something they care about, and neither do I. They actually do care about managing expectations, but they suck at it. I mentioned the neurodivergent thing. Normies have a hard time understanding them, and vice versa. Less confusion when you understand this
English

@Michigan_Value How in the world can management be unaware of how important it is to manage expectations? It is mind-boggling to me that they seem so tone-deaf to this issue. It is why the stock is a disaster rather than a momentum play.
English

@RevShark I hear this sort of thing all the time. I know these guys pretty well. They don't give a crap about promotion, have zero idea how to run IR, and are obsessively focused on building the business as only neurodivergent folks can be.
English

I told you months ago that $HROW management was making the classic mistake of overpromising and underdelivering. They did it again this quarter and have really lost credibility. I am hoping they have finally learned their lesson, but they seem more concerned about promotion rather than managing expectations.
English

@RRoyceNYC it's more complicated than that. no, it won't recur
English

@Biomaven C 6% and shrinking, X 18% down from 24%
English

@Michigan_Value What is current market share for Cequa and Xiidra?
English

@dorb2sQ nah, I don't need to waste time lecturing them. they know the market didn't like guidance. I only get 30 minutes a quarter with mgmt so best to use it otherwise
English







